Q-omics provides the consensus-scored RWDD4 profile across patient tissues and cancer cell-line models. RWDD4 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RWDD4 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, RWDD4 RNA expression shows 19,257 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, THCA, and ACC as cancer lineages where RWDD4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RWDD4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RWDD4 survival associations across molecular data types. RWDD4 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RWDD4 RNA expression–survival associations across cancer types. High RWDD4 expression shows unfavorable associations in MESO, LGG, CESC, LIHC, ACC and SCLC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify MESO as the clearest survival context for RWDD4 RNA expression.
This table summarizes RWDD4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for RWDD4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RWDD4 shows lower tumor expression in THCA and higher tumor expression in HNSC, LUSC, LUAD, CHOL and LIHC. The THCA box plot shows higher RWDD4 RNA expression in normal versus tumor tissue (log2 FC = −1.135, t-test p < 0.001).
This table shows molecular features associated with RWDD4 in patient tissues and cancer cell lines. In patient samples, RWDD4 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RWDD4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
